

(12) **UK Patent Application** (19) **GB** (11) **2 189 144** (13) **A**

(43) Application published 21 Oct 1987

(21) Application No **8709166**

(22) Date of filing **16 Apr 1987**

(30) Priority data

(31) **1623**

(32) **18 Apr 1986**

(33) **HU**

(71) Applicant

EGIS Gyógyszergyár

(Incorporated in Hungary)

30-38 Kereszturi ut, Budapest X, Hungary

(72) Inventors

Gyula Sebestyén

István Simonyi

Gizella Mitholics

Márta Kovács

Frigyes Görgényi

Márton Fekete

(51) INT CL⁴

A61K 31/315

(52) Domestic classification (Edition I):

A5B 170 284 28Y H

U1S 2410 A5B

(56) Documents cited

None

(58) Field of search

A5B

Selected US specifications from IPC sub-class A61K

(72) continued

Pál Vágó

István Seres

János Egri

Mária Szeli


(74) Agent and/or Address for Service

T. Z. Gold & Company,

9 Staple Inn, London WC1V 7QH

(54) **Antifungal pharmaceutical composition comprising an organic zinc complex**

(57) A topical pharmaceutical composition having antimycotic activity comprises the zinc complex of 5-chloro-7-iodo-8-hydroxy-quinoline of formula (I) and a topically acceptable carrier.




GB 2 189 144 A

SPECIFICATION

A pharmaceutical composition comprising an organic zinc complex and a process for preparing the active substance

The invention refers to a novel pharmaceutical composition having especially antimycotic activity and to a process for preparing the active substance being the zinc complex of 5-chloro-7-iodo-8-hydroxy-quinoline of formula (I)



5-Chloro-7-iodo-hydroxyquinoline is known to have antibacterial activity, thus, it is employed for the treatment of amoebic colitis (A. Burger, Medicinal Chemistry, 1, p. 540, Wiley-Interscience, New York, 1970).

The zinc chelate of 5-chloro-7-iodo-8-hydroxyquinoline of the formula (I) was used for analytical determinations (Acta Pharm. Hung., 32, 246). Also the solubility of the complex of formula (I) was investigated (Chem. Abstr., 50, 652d) and the determination of the complex by mass spectrometry was described [Chem. Abstr., 83, 157288m (1975)].

5-Chloro-7-iodo-8-hydroxyquinoline labelled with ^{14}C was reacted with ^{65}Zn ions to give the corresponding labelled chelate that was used for the treatment of rabbits, and the concentration of the chelate in the tibial nerve was determined [Chem. Abstr., 88, 108h (1978)].

In summary, it can be established that in the prior art there is no indication of a therapeutically valuable biological activity of the complex of the formula (I), furthermore, an economical process for preparation the complex is not known, either.

Now it has been found that the complex of formula (I) has an extremely high antimycotic activity as shown by the following in vitro tests.

The antimycotic activity of the complex of formula (I) was compared with that of 5-chloro-7-iodo-8-hydroxyquinoline on the following fungus strains:

- Trichophyton mentagrophyte (A)
- Microsporum canis (B)
- Candida albicans (C)
- Aspergillus niger (D)

The tests were performed according to the prescriptions of the United States' Pharmacopoeia XXI on an ointment comprising 0.04 per cent of the complex of formula (I) and 0.036 per cent of 5-chloro-7-iodo-8-hydroxyquinoline, respectively. Ointment samples prepared aseptically and weighing 50 g were artificially infected with the cells and spores, respectively, of the micro-organisms listed above to obtain a starting germ count of about $5 \times 10^5/\text{g}$. Aliquots of 1 g were removed from the samples directly after the infection (time 0), then after 1, 2, 3, 4, 5, 6 and 7 days, and the germ count was determined in each case by means of the plate pouring method. Three parallel tests were performed with both compounds and the four strains of fungi. The average values of the results obtained are given in Table 1.

Table 1
In vitro antimycotic activity

Micro-organism	Compound	Germ count					
		0 hour	1 day	2 days	3 days	4 days	5 days 6 days 7 days
A	Zinc complex of 5-chloro-7-iodo-8-hydroxyquinoline	6.65×10^5	8.1×10^4	\emptyset	\emptyset	\emptyset	\emptyset
	5-Chloro-7-iodo-8-hydroxyquinoline	6.55×10^5	4.1×10^4	3.5×10^4	2.5×10^3	2.5×10^3	2.8×10^2
B	Zinc complex of 5-chloro-7-iodo-8-hydroxyquinoline	4.2×10^5	1.1×10^5	2×10^4	1.4×10^2	\emptyset	\emptyset
	5-Chloro-7-iodo-8-hydroxyquinoline	3.8×10^5	3.1×10^4	3.15×10^4	2.6×10^3	1.2×10^3	10^2
C	Zinc complex of 5-chloro-7-iodo-8-hydroxyquinoline	6.1×10^5	2.1×10^3	1.8×10^2	\emptyset	\emptyset	\emptyset
	5-Chloro-7-iodo-8-hydroxyquinoline	6.22×10^5	4.2×10^5	3.8×10^4	2.1×10^4	5.4×10^3	5.2×10^3
D	Zinc complex of 5-chloro-7-iodo-8-hydroxyquinoline	5.5×10^5	3.2×10^4	1.35×10^2	\emptyset	\emptyset	\emptyset
	5-Chloro-7-iodo-8-hydroxyquinoline	5.4×10^5	4.1×10^5	4.0×10^4	3.1×10^3	1.4×10^2	2×10

From Table 1 it can be seen that the germ count is lowered to zero by the zinc complex of 5-chloro-7-iodo-8-hydroxyquinoline in a much shorter time than by the 5-chloro-7-iodo-8-hydroxyquinoline in case of each microorganism tested. Thus, the samples comprising the zinc complex of formula (I) and infected with the strain *Trichophyton mentagrophytes* become free from germs already on day 2, while the samples containing 5-chloro-7-iodo-8-hydroxyquinoline need 6 days to become germ-free.

It is surprising for an expert that the complex of the formula (I) exerts a powerful antimycotic action in a much shorter time than the corresponding zinc-free compound, i.e. 5-chloro-7-iodo-8-hydroxyquinoline.

The dermal toxicity of the complex formula (I) was determined on rats (CFY) weighing about 180 g at the beginning of the test. Each group consisted of 5 male and 5 female rats.

The animals were anaesthetized with ether and a dorsal skin surface measuring 5cm by 5cm was shaved, then covered with an ointment comprising 10 per cent of the compound formula (I). The dosage was 10 g of ointment/1 kg of body weight.

The animals were exposed to the ointment for 24 hours, then observed for any signs of toxicity during 14 days. Neither toxic clinical symptoms, nor mortality were experienced. The hair growth of the treated rats was normal for these species.

Thus, the complex formula (I) did not show any dermal toxicity in a dosage of 1 g/kg.

From the above test results it can be concluded that the zinc complex of 5-chloro-7-iodo-8-hydroxyquinoline of formula (I) can be used for the therapy of mycosis. In the therapy, the patient is treated with a therapeutically active amount of a compound of formula (I) or a pharmaceutical composition comprising it.

The pharmaceutical composition of the invention comprises the zinc complex of 5-chloro-7-iodo-8-hydroxyquinoline of formula (I) and one or more pharmaceutically acceptable carrier(s).

The pharmaceutical compositions of the invention can be solid or liquid. The solid pharmaceutical compositions may be powders, dusting powders, ointments, vaginal suppositories, capsules, tablets, dragées etc. The liquid pharmaceutical compositions can be emulsions, suspensions, gels etc. The emulsions or suspensions of the invention can be converted to aerosols, too, by means of propellants.

The pharmaceuticals composition of the invention contains, in general, 0.1 to 90 per cent of the complex of formula (I).

Preferred pharmaceutical compositions of the invention are ointments, vaginal suppositories and dusting powders being suitable in the first place for local treatment. For systemic treatment, preferred pharmaceutical compositions can be capsules, tablets for dragées.

The daily dosage of the compound of the formula (I) is, in general, about 0.01mg to 1 g depending on various factors such as the state and weight of the patient, dosage form etc.

The pharmaceutical composition of the invention comprises pharmaceutically acceptable carrier(s) in addition to the active substance (see e.g. Remington's Pharmaceutical Sciences, 16th Edition; Mack Publishing Company, Easton, USA, 1980).

Preferred carriers are: water; alkanols, for example monobasic alcohols such as isopropanol or cetyl-stearyl alcohol, dibasic alcohols such as poly(ethylene glycol), tribasic alcohols such as glycerol; fat-like substances, for example triglycerides of fatty acids; fatty acids or the metal salts thereof such as stearic acid, magnesium stearate or zinc stearate; liquid or solid hydrocarbons such as liquid paraffin or vaseline; silica or silicates such as bentonite or talc; metal oxides such as zinc oxide; alginic acid, salts and esters thereof; poly(vinyl-pyrrolidone); polysaccharides such as starch; cellulosic derivatives such a cellulose ethers and cellulose esters; polymers such as polymethacrylates; surface active agents such as alkyl ethers of poly(ethylene glycol) or sorbitane esters of fatty acids; buffers and agents for pH control such as sodium acetate or triethanol amine; preservatives such as methyl p-hydroxybenzoate; etc.

The pharmaceutical compositions of the invention are prepared by mixing the complex of formula (I) with one or more suitable carrier(s) in a manner known per se.

The pharmaceutical compositions of the invention can be employed for the effective treatment of mycotic infections on the skin surface, mucous membranes or nails. For this purpose, the infected area is contacted with a therapeutically active amount of the complex of formula (I), or a therapeutically active amount of it is administered to the patient having mycotic infection.

The complex of formula (I) can be prepared from 5-chloro-7-iodo-8-hydroxyquinoline by essentially salt formation or from the corresponding zinc complex of 8-hydroxyquinoline by chlorination and iodination or from the corresponding zinc complex of 5-chloro-8-hydroxyquinoline by iodination or from the corresponding zinc complex of 7-iodo-8-hydroxyquinoline by chlorination.

It is preferred to react a solution of an alkali metal salt – preferably sodium or potassium salt – of 5-chloro-7-iodo-8-hydroxyquinoline with a solution comprising an excess of an organic or inorganic zinc salt or a zinc complex having a lower stability constant than that of the compound of formula (I) and to separate the product precipitated.

In general, the zinc reactant is taken in excess as compared to the amount required by stoichiometry. Preferably, an excess of 10 to 30 per cent is used.

For the complex formation, preferred zinc salts include zinc sulfate, zinc chloride, zinc acetate etc. The zinc complexes used as zinc reagent must have a lower stability than that of the compound of formula (I). Preferred zinc complexes include alkali tetrahydroxo zincate, zinc tetrammine hydroxide etc.

- 5 To prepare the solution of the alkali metal salt of 5-chloro-7-iodo-8-hydroxyquinoline as well as 5 of the zinc reagent, solvents such as water, alkanols, e.g. methanol or ethanol, dimethyl formamide etc. or a mixture thereof are employed.

The alkali metal salt of 5-chloro-7-iodo-8-hydroxyquinoline is prepared from 5-chloro-7-iodo-8-hydroxyquinoline with an equimolar amount of an alkali metal hydroxide, then the solution of the 10 zinc reagent is added to the solution of the alkali metal salt of 5-chloro-7-iodo-8-hydroxyquinoline. The suitable reaction medium dissolves the alkali metal salt of 5-chloro-7-iodo-8-hydroxyquinoline but practically does not dissolve the complex of formula (I). Preferred reaction media are mixtures of methanol and water. If necessary, the mother liquor of the compound of formula (I) can be, of course, concentrated by evaporation.

- 15 According to a preferred process of the invention, the complex of formula (I) can be prepared 15 in a yield of about 85 per cent. The purity of the product is suitable for pharmaceutical purposes.

The complex of formula (I) can be prepared also from a solution of 5-chloro-7-iodo-8-hydroxyquinoline by means of a cation exchange resin. In this case, zinc ions are bound to the cation 20 exchange resin by treating the resin with a solution comprising zinc ions such as an aqueous zinc chloride solution, then the resin is eluted with a solution of 5-chloro-7-iodo-8-hydroxyquinoline in e.g. dimethyl formamide, and the eluate is concentrated.

Although the preparation of the zinc complexes of 8-hydroxyquinoline and halogenated 8-hydroxyquinolines is known, no teaching is available for the economical manufacture of the 25 complex formula (I).

The invention is further elucidated by means of the following Examples, without limiting the scope claimed.

Example 1

30 The solution of 22.0 g (0.55 mole) of sodium hydroxide in 150 ml of water is quickly added 30 to 163.0 g (0.53 mole) of 5-chloro-7-iodo-8-hydroxyquinoline suspended in 1500 ml of methanol at 30 °C. The mixture is stirred and after 2 to 2.5 hours a dark green solution is obtained. To this solution comprising the sodium salt of 5-chloro-7-iodo-8-hydroxyquinoline in methanol, the 35 solution of 95.0 g (0.33 mole) of zinc sulfate heptahydrate in 250 ml of water is added at room temperature. The yellow, compact solid formed is stirred for further 3 hours, then filtered and 35 thoroughly washed with water. The product is dissolved in a mixture of 600 ml of dimethyl formamide and 50 ml of water under boiling, treated with 10 g of active carbon, filtered and the filtrate is stirred at 25 °C for 8 hours. The precipitate is filtered, suspended in 300 ml of 40 methanol, the suspension obtained is stirred for 1 hour at the boiling point of the methanol, then cooled to room temperature. The product is filtered and dried to constant weight at 80 °C.

In this way, 138.0 g of the zinc complex of 5-chloro-7-iodo-8-hydroxyquinoline are obtained. Yield: 82 per cent. M.p.: 280 °C (under decomposition).

Analysis for $C_{18}H_8Cl_2I_2N_2O_2Zn$

calculated: C 32.05 %, H 1.20 %, N 4.15 %, I 37.63 %, Zn 9.69%;

45 found: C 32.70 %, H 1.30 %, N 4.04 %, I 37.03 %, Zn 9.97 %. 45

Example 2

The procedure of Example 1 is repeated but the aqueous solution of zinc sulfate heptahydrate is replaced by the solution of 60.0 g (0.33 mole) of zinc chloride comprising 25 per cent of 50 crystal water in 250 ml of water. 145.5 g of the zinc complex of 5-chloro-7-iodo-8-hydroxyquinoline are obtained. Yield: 86.5 per cent. M.p.: 280 °C (under decomposition). 50

Example 3

The process of Example 1 is repeated but 72.4 g (0.33 mole) of zinc acetate dihydrate in 250 55 ml of water are used as the zinc reagent. Thus, 123.0 g of the zinc complex of 5-chloro-7-iodo-8-hydroxyquinoline are obtained. Yield: 73 per cent. M.p.: 282 °C (under decomposition). 55

Example 4

The procedure of Example 1 is repeated with the modification that a solution of sodium 60 tetrahydroxo zincate $[Na_2Zn(OH)_4]$ in water is used as the zinc reagent. Thus, 108.2 g of the zinc complex of 5-chloro-7-iodo-8-hydroxyquinoline are obtained. Yield: 64 per cent. M.p.: 282 °C (under decomposition). 60

The solution of sodium tetrahydroxo zincate is prepared as follows: 93.7 g (0.33 mole) of zinc sulfate heptahydrate are dissolved in 125 ml of water, and the solution obtained is added to 65 28.0 g (0.7 mole) of sodium hydroxide in 125 ml of water. The solution thus obtained is 65

reacted with the sodium salt of 5-chloro-7-iodo-8-hydroxyquinoline.

Example 5

The procedure of Example 1 is repeated with the difference that an aqueous solution of zinc tetrammine hydroxide $[\text{Zn}(\text{NH}_3)_4(\text{OH})_2]$ is used as zinc reagent. Thus, 114.0 g of the zinc complex of 5-chloro-7-iodo-8-hydroxyquinoline are obtained. Yield: 67 per cent. M.p.: 282 °C (under decomposition).

The solution of zinc tetrammine hydroxide is prepared as follows: 100 ml of concentrated aqueous ammonia is poured to 93.7 g (0.33 mole) of zinc sulfate heptahydrate in 150 ml water, and the solution obtained is reacted with the sodium salt of 5-chloro-7-iodo-8-hydroxyquinoline.

Example 6

Ointment (of hydrophilic character)
zinc complex of 5-chloro-7-iodo-8-

15	hydroxyquinoline	10 g	15
	stearine	2.7 g	
	paraffin oil	12.6 g	
	cetyl-stearyl alcohol	4.5	
	wax (cera alba)	0.9 g	
20	vaseline (white)	4.5 g	20
	Brij [®] 58 [poly(ethylene glycol) cetyl ether, degree of polymerisation: 20, manufacturer: Atlas]	1.8 g	
	Span [®] 60 (sorbitane monostearate, manufacturer: Atlas)	2.25 g	
25	methyl p-hydroxybenzoate	0.18 g	25
	distilled water	to 100 g	

The stearine, paraffin oil, cetyl-stearyl alcohol, vaseline and Span[®] 60 are melted at about 80 °C, stirred and filtered (lipophilic phase). The methyl p-hydroxybenzoate and Brij[®] 58 are dissolved in the distilled water under boiling, the solution obtained is filtered and cooled to about 70 °C. The warm aqueous solution is added to the lipophilic phase of 65 °C in several portions under stirring. An emulsion of the type oil in water is obtained which is left to cool under stirring. Then, the zinc complex of 5-chloro-7-iodo-8-hydroxyquinoline is added in small portions under stirring and the composition is homogenized for 15 minutes. The homogeneous ointment is filled into tubes.

Example 7

Ointment (of lipophilic character)

40	zinc complex of 5-chloro-7-iodo-8-hydroxyquinoline	8.0 g	40
	vaseline (white)	20.0 g	
	paraffin oil	52.0 g	
	cholesterol	1.4 g	
45	Miglyol [®] 812 (a mixture of tri-glycerides of saturated fatty acids of vegetable origin, manufacture: Dynamit-Nobel)	2.5 g	45
	Span [®] 60	2.6 g	
50	distilled water	to 100.0 g	50

The procedure of Example 6 is followed. At first, the vaseline, paraffin oil, cholesterol, Miglyol[®] are melted together, then the water is added, and the active substance is suspended in the emulsion of the type water in oil.

Example 8

Hydrogel

zinc complex of 5-chloro-7-iodo-8-hydroxyquinoline

6.0 g

Carbopol[®] 934 (colloidal carboxyvinyl)

0.9 g

5 polymer, manufacturer: Biesterfeld)

5

triethanolamine

1.0 g

methyl p-hydroxybenzoate

0.1 g

isopropanol

32.0 g

distilled water

to 100.0 g

10

10

The methyl p-hydroxybenzoate is dissolved in a part of the distilled water. Carbopol[®] 934 is swollen in the solution obtained, then neutralized with the triethanolamine. After the addition of a suspension of the active substance is isopropanol, the volume is adjusted with distilled water to 100 g.

15

15

Example 9

Gel

zinc complex of 5-chloro-7-iodo-8-hydroxyquinoline

8.0 g

20 Carbowax 6000 [poly(ethylene glycol) monoalkyl ether, degree of polymerisation: 6000]

15.0 g

20

Carbowax 300 [poly(ethylene glycol) monoalkyl ether, degree of polymerisation: 300]

30.0 g

25 Carbowax 400 [poly(ethylene glycol) monoalkyl ether, degree of polymerisation: 400]

27.0 g

25

glycerol

18.0 g

Brij³⁵ [poly(ethylene glycol) lauryl ether, degree of polymerisation: 23, manufacturer: Atlas]

2.0 g

30

30

The components, with the exception of the active substance, are melted together, the active substance is added to the melt in small portions under stirring, and the composition is homogenized.

35 Example 10

35

Vaginal suppository (pressed)

zinc complex of 5-chloro-7-iodo-8-hydroxyquinoline

0.4000 g

40 poly(ethylene glycol) (degree of polymerisation: 35,000)

0.0087 g

40

talc

0.0086 g

magnesium stearate

0.0100 g

Aerosil R-200 (active silica, manufacturer: Degussa)

0.0030 g

45 Mowilith DH, 100 per cent (vinyl acetate) polymer, manufacturer: Hoechst AG)

0.0200 g

45

potatoe starch

0.0240 g

ultra amylopectine

0.0087 g

50 Avicel[®] PH 101 (microcrystalline cellulose)

0.0170 g

50

0.5000 g

55 The components are homogenized in a fluidization apparatus under the following parameters:

inlet air temperature: 50 to 55 °C

outlet air temperature: 26 °C

pressure at the injector: 3 bar

flow rate of air: 3000 to 4000 m³/hr.

55

60 rate of addition: 800 ml/min.

60

water content of the granulate: 0.5 to 1.5 per cent

disintegration time of the granulate: about 10 minutes.

The granulate is pressed to obtain vaginal suppositories.

65 Example 11

65

Vaginal suppository (moulded)
zinc complex of 5-chloro-7-iodo-8-

-hydroxyquinoline 0.4 g

Tween^(R) 61 (polyoxyethylene sorbitane 0.6 g

5 monostearate, manufacturer: Atlas) 5

Miglyol 812 0.8 g

Witepsol W 25 (artificial triglyceride of 2.5 g

coco and palm oil, manufacturer:

Dynamit-Nobel)

10

Moulding is performed at a temperature of 38 to 41 °C under constant stirring.

10

Example 12

15 Dusting powder 15

zinc complex of 5-chloro-7-iodo-8-
-hydroxyquinoline

14.0 g

zinc stearate 5.0 g

zinc oxide 4.5 g

20 Aerosil^(R) R-200 20

talc 3.8 g

to 100.0 g

The components are thoroughly homogenized to obtain a powder mixture.

25 Example 13 25

Suspension

zinc complex of 5-chloro-7-iodo-8-

hydroxyquinoline 0.1 g

Brij^(R) 30 [poly(ethylene glycol) lauryl ether, 1.7 g

30 degree of polymerisation: 4, 30

manufacturer: Atlas]

sodium citrate 2.5 g

methyl p-hydroxybenzoate 0.1 g

Keltrol^(R) (polysaccharide prepared by 4.2 g

35 fermentation) 35

distilled water to 100.0 g

The methyl p-hydroxybenzoate is dissolved in a part of the distilled water, then Keltrol^(R) is swollen in the solution obtained. The sodium citrate and Brij^(R) 30 are dissolved in the remaining part of the distilled water. The active substance is added to the latter solution, then it is completed with the swollen Keltrol^(R). The mixture is passed through a colloid mill to achieve the homogenization required.

40

40


Instead of Keltrol^(R), the following substances can be used: alginic acid, sodium alginate, esters of alginic acid, poly(vinyl pyrrolidone), cellulosic derivatives, polymethacrylates or bentonite.

45

45

CLAIMS

1. A pharmaceutical composition having especially mycotic activity, comprising the zinc complex of 5-chloro-7-iodo-8-hydroxyquinoline of formula (I)



25 and one or more pharmaceutically acceptable carrier(s). 25

2. The pharmaceutical composition of Claim 1, comprising 0.1 to 90 per cent of the complex of formula (I).


3. The pharmaceutical composition of Claim 1 or 2 being in form of an ointment, vaginal suppository or dusting powder.

30 4. A process for preparing a pharmaceutical composition having antimycotic activity, in which the zinc complex of 5-chloro-7-iodo-8-hydroxyquinoline of formula (I) is mixed with one or more pharmaceutically acceptable carrier(s) and the mixture is transformed into a pharmaceutical composition. 30

5. The process of Claim 4, in which the complex of formula (I) is used in a concentration of 35 0.1 to 90 per cent. 35

6. The process of Claim 4 or 5, in which the mixture of the complex of formula (I) and the carrier(s) are transformed into an ointment, vaginal suppository or dusting powder.

7. A process for preparing the zinc complex of 5-chloro-7-iodo-8-hydroxyquinoline of formula (I) 40 (I) 40



in which a solution of an alkali metal salt of 5-chloro-7-iodo-8-hydroxyquinoline is reacted with a 65 solution containing an excess of an inorganic or organic zinc salt or a zinc complex having a

lower stability constant than that of the complex of formula (I) and the product precipitated is separated.

8. The process of Claim 7, in which the inorganic zinc salt is zinc sulfate or zinc chloride.

9. The process of Claim 7, in which the organic zinc salt is zinc acetate.

5 10. A method for treating the symptoms of mycotic disorders, in which the patient is treated with a therapeutically active amount of a complex of the formula (I) or a pharmaceutical composition comprising it. 5

11. Use of the zinc complex of 5-chloro-7-iodo-8-hydroxyquinoline in the manufacture of a medicament for use in treating mycotic disorders or diseases.

10 12. A pharmaceutical composition substantially as hereinbefore described in any one of Examples 6 to 13. 10

13. A process as claimed in claim 4 substantially as hereinbefore described in any one of Examples 6 to 13.

15 14. A process as claimed in claim 7, substantially as hereinbefore described in any one of Examples 1 to 5. 15